Positive Long-term Outcomes with HeartFlow FFRCT and Plaque Analysis Demonstrated in ADVANCE-DK Registry at TCT 2024
October 27, 2024 08:15 ET
|
HeartFlow Holding, Inc.
— Data confirm the use of FFRCT and Plaque Analysis helps assess long-term risks, informing more personalized and effective treatment plans for patients with coronary artery disease -– FFRCT further...
HeartFlow Announces Favorable Coverage Determination for Plaque Analysis by Four Medicare Administrative Contractors
October 11, 2024 12:27 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the global leader in non-invasive artificial intelligence (AI) heart care solutions, today announced HeartFlow Plaque...
HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease
July 18, 2024 09:00 ET
|
HeartFlow Holding, Inc.
Technology offers benefits of HeartFlow Plaque Analysis with the new addition of 3D interactive capabilities, integrated with lesion specific FFRCT values WASHINGTON, July 18, 2024 (GLOBE...
SCCT 2024: HeartFlow to Present New Data on Coronary Artery Disease Management with Coronary Computed Tomography Angiography
July 16, 2024 12:00 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- HeartFlow, a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced it will be presenting new findings on...
HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage
June 03, 2024 12:00 ET
|
HeartFlow Holding, Inc.
HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage
HeartFlow's Plaque Analysis Leading The Way: 95% Accuracy vs Invasive Imaging In Newly Published REVEALPLAQUE Study
May 15, 2024 12:00 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that the data from its...
HeartFlow Initiates DECIDE Registry to Evaluate Utility of HeartFlow AI-Enabled Plaque Analysis for Patients with Suspected Coronary Artery Disease
March 26, 2024 14:00 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the leader in AI-driven healthcare technology, today announced the launch of the DECIDE Registry, the largest prospective...
HeartFlow Achieves Landmark Milestone of 250,000 Patients Assessed for Coronary Artery Disease (CAD) with FFRCT Analysis
January 03, 2024 09:00 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) precision coronary care solutions, today announced that it has...
TCT 2023: HeartFlow Presents Clinical Data Featuring First Solution Offering Lesion-Specific Insights
October 25, 2023 11:00 ET
|
HeartFlow Holding, Inc.
New Clinical Data Support Use of Lesion-Specific FFRCT for Diagnosis and Treatment of Patients With Coronary Artery Disease
HeartFlow Receives FDA 510(k) Clearance for its Plaque Analysis and RoadMap™ Analysis
October 18, 2022 10:00 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the leader in revolutionizing precision heart care, has received U.S. Food and Drug Administration (FDA) 510(k) clearance on...